Skip to main content

Market Overview

Weakness in Aratana Shares An 'Excellent' Entry Point

Share:

Aratana Therapeutics Inc (NASDAQ: PETX) seems to be firing on all cylinders and the recent weakness in shares represents an attractive buying opportunity, Lake Street Capital Markets’ Carl Byrnes said in a report. He reiterated a Buy rating on the company, with a price target of $15.

Analyst Carl Byrnes expressed optimism regarding Aratana Therapeutics being able to emerge as a leading innovator in the companion animal veterinary medicines market. He added, “We perceive the recent weakness as a major buying opportunity.”

Commercialization On The Horizon

Byrnes mentioned that Aratana Therapeutics appears to be on track to commercializing four NCEs this year:

  • Galliprant: Approved in March - For control of inflammation and pain associated with osteoarthritis
  • Entyce: Approved in May - A breakthrough first-in-class therapeutic for appetite stimulation
  • Nocita: ADUFA approval date of August 28 - Liposomal bupivacaine that provides for long duration post-operative pain management
  • AT-014 - An immune-vaccine for post-operative treatment of osteosarcoma

Galliprant, Entyce and Nocita seem to be well positioned to becoming blockbuster therapies in the companion animal segment, the analyst added.

Did you like this article? Could it have been improved? Please email feedback@benzinga.com to let us know!

Latest Ratings for PETX

DateFirmActionFromTo
Apr 2019Credit SuisseDowngradesOutperformNeutral
Jan 2019William BlairDowngradesOutperformMarket Perform
Jan 2019StifelDowngradesBuyHold

View More Analyst Ratings for PETX

View the Latest Analyst Ratings

 

Related Articles (PETX)

View Comments and Join the Discussion!

Posted-In: Carl Byrnes Lake Street Capital MarketsAnalyst Color Long Ideas Reiteration Analyst Ratings Trading Ideas

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com